Ad hoc: GPC Biotech AG: GPC Biotech Reports that Marketing Authorization Application forSatraplatin is to be Withdrawn

GPC Biotech AG / Misc. matters / GPC Biotech Reports that Marketing 
Authorization Application for
Satraplatin is to be Withdrawn
 
Ad hoc announcement according to §15 WpHG processed and transmitted 
by Hugin ASA. The issuer is solely responsible for the content of 
this announcement.     
 
----------------------------------------------------------------------
--------------
 
Martinsried/Munich (Germany) and  Princeton, N.J.,   July 25, 2008  -
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) reported
that the Company has been informed by its partner for satraplatin  in
Europe  that  they  plan  to  withdraw  the  Marketing  Authorization
Application (MAA) for satraplatin  plus prednisone for the  treatment
of  hormone-refractory   prostate   cancer   patients   whose   prior
chemotherapy has  failed.   This decision  was  based on  a  list  of
outstanding issues  received following  review by  the Committee  for
Medicinal Products for  Human Use  (CHMP) of  the European  Medicines
Agency (EMEA) of the filing, which indicates that the opinion of  the
Committee is that the application  is currently not approvable  based
on the information provided. GPC Biotech is working closely with  its
partners to determine  the next  steps regarding  the development  of
satraplatin.
 
End of Ad Hoc Announcement
 
This ad hoc announcement  contains forward-looking statements,  which
express the current beliefs and expectations of the management of GPC
Biotech, including  statements  about  the  efficacy  and  safety  of
satraplatin.  Such statements are  based on current expectations  and
are subject to risks and uncertainties, many of which are beyond  our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or  implied  by  such  forward-looking  statements.  Actual
results could differ materially depending on a number of factors, and
we  caution   investors  not   to  place   undue  reliance   on   the
forward-looking statements  contained in  this ad  hoc  announcement.
Satraplatin may not be approved for marketing in a timely manner,  if
at all.  We direct  you to GPC Biotech's  Annual Report on Form  20-F
for the fiscal year ended December  31, 2007 and other reports  filed
with the  U.S.  Securities  and Exchange  Commission  for  additional
details on the important factors that may affect the future  results,
performance  and   achievements  of   GPC  Biotech.   Forward-looking
statements speak only as of the date  on which they are made and  GPC
Biotech undertakes  no  obligation to  update  these  forward-looking
statements, even if new information becomes available in the future.
 
Satraplatin has not been approved by the FDA in the U.S., the EMEA in
Europe or any other  regulatory authority and  no conclusions can  or
should be  drawn  regarding its  safety  or effectiveness.  Only  the
relevant regulatory authorities can determine whether satraplatin  is
safe and effective for the use(s) being investigated.
 
For further information, please contact:
 
GPC Biotech AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
 
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609-524-5884
usinvestors@gpc-biotech.com
 
Additional media contacts for Europe:
MC Services AG
Phone:  +49 (0) 89 210 228 0
 
Raimund Gabriel
raimund.gabriel@mc-services.eu
 
Hilda Juhasz
hilda.juhasz@mc-services.eu
 
Additional investor contact for Europe:
Trout International LLC
Mike Booth, Senior Vice President
Phone: +44 207 936 9326
mbooth@troutgroup.com
 
--- End of Message  ---
 
GPC Biotech AG
Fraunhoferstr. 20 Martinsried 
 
WKN: 585150; ISIN: 
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, 
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Düsseldorf, 
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Geregelter Markt in Frankfurter Wertpapierbörse;